Neurotez, Inc. Awarded Multi-Million Dollar National Institutes of Health (NIH) Grant to Advance a Leptin Product into Clinical Trials for Treating Alzheimer's Disease

Published: Aug 04, 2009

BRIDGEWATER, N.J.--(BUSINESS WIRE)--The National Institutes of Health (NIH), through the Small Business Innovation and Research (SBIR) Program, has awarded Neurotez, Inc. a $2.73-million dollar, three-year grant to initiate the clinical development of a Leptin product as a novel therapy for Alzheimer’s disease. Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain and is often decreased in patients with Alzheimer’s disease. The Neurotez approach is based on restoration of Leptin levels.

Back to news